Searched for
INVESTMENT STRATEGIES IN PHARMA
Anupam Rasayan completes Bliss GVS deal, targets Rs 4,000-crore integrated platformAnupam Rasayan India Limited has finalised its acquisition of a controlling interest in Bliss GVS Pharma, marking a strategic expansion int...- Why is market falling today? Sensex slumps 700 points, Nifty below 22,600. 8 key factors rattling D-StreetStock market Down Today: On Tuesday, the Indian stock market faced a substantial downturn. This sharp decline came after a previous drop ex...
- Market veterans favour value plays over crowded, expensive themesMarket experts project cautious optimism for Indian equities as valuations become less demanding and earnings growth aligns. Large-cap stoc...
- F&O Talk: 23,270 is a key Nifty hurdle; Sudeep Shah picks 5 stocks, discusses PB Fintech, Turtlemint strategyNifty ended at 23,140.50 after an eighth consecutive weekly decline, with technical indicators remaining bearish. Analysts identify 23,300 ...
- Jagsonpal Pharma to acquire Group Pharma’s wellness portfolioJagsonpal Pharmaceuticals has signed a business transfer agreement to acquire the wellness portfolio of Group Pharmaceuticals. The acquisit...
- Rs 1.68 crore investments, Rs 89,000 monthly MF SIP. Can this 40-year-old investor retire at 50?A 40-year-old investor based in Pune is on a mission to retire by age 50 while providing for her two children’s education. With savings of ...
- NFO Alert: Tata Mutual Fund announces launch of Titanium Active Asset Allocator Long-Short FundTata Mutual Fund has launched the Titanium Active Asset Allocator Long-Short Fund, a multi-asset strategy under its SIF framework. The mark...
- Sunil Singhania-led Abakkus Mutual Fund announces launch of its SIF platform FokkusAbakkus Mutual Fund, led by Sunil Singhania, has received SEBI approval to launch its Specialised Investment Fund (SIF) platform under the ...
- MF Tracker: HDFC Pharma & Healthcare Fund tops equity MFs at 25% in 1 year. Should investors chase the rally?HDFC Pharma and Healthcare Fund recorded an impressive 25% return in the last year, surpassing its category average across various time fra...
- Aragen steps up investment in complex drug modalities; plans 500 KL new CDMO capacityAragen Life Sciences is increasing investments in complex drug modalities and manufacturing. The company plans to add significant small-mol...
- JioBlackRock CIO Rishi Kohli decodes Nifty’s inflection point after two years of weak returnsJioBlackRock CIO Rishi Kohli says largecap valuations have de-rated, while Indian banks have underperformed global peers, creating potentia...
- EQT Group plans to invest $50 billion in India by 2030: Jean Eric Salata, ChairmanSwedish buyout firm EQT plans to invest $50 billion in India over the next four years, roughly twice the $26 billion it has invested since ...
- Quant Mid Cap Fund exits ICICI Bank, 2 others and adds 5 stocks in AugustQuant Mid Cap Fund exited ICICI Bank, Ambuja Cements and L&T Technology Services in August, while adding six stocks including IDBI Bank, Co...
- Smallcap, midcap stocks give 85 multibaggers but pro investors are betting elsewhereIn 2023, while small and mid-cap stocks experienced notable increases, a trend among professional investors is emerging towards largecap co...
- Gorilla investing and 34% return: How Mihir Vora made Trust Smallcap Fund top performerTrust Smallcap Fund has emerged as the best performing fund in its category over the past year, delivering a 34% return as investors reasse...
- Invesco’s ₹16,000 crore midcap fund delivered 426% return in 10 years. Aditya Khemani reveals the strategyInvesco India Midcap Fund has impressively delivered a 426% return over a decade, showcasing an investment strategy that values robust earn...
- W Health Ventures closes second fund at Rs 700 croreThe second fund has so far incubated two companies: cancer-care platform Everhope Oncology, built in partnership with Narayana Health, and ...
- Smallcap mutual funds outperform with 21% return in 6 months. Should investors chase the rally or wait for correction?In the past six months, smallcap mutual funds have delivered excellent returns, prompting investors to reassess their future investment pla...
- Sun Pharma agrees to lower US drug prices under Trump plan; analysts see limited financial impactSun Pharmaceutical Industries will offer its drugs at prices matching other developed nations. This agreement aims to make healthcare affor...
- Sun Pharma to extend MFN pricing to US state Medicaid programmesSun Pharma ranks second in US dermatology by prescriptions, with key brands including Ilumya for plaque psoriasis and Winlevi for acne. Rec...
Load More
